JP2013532729A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532729A5 JP2013532729A5 JP2013523271A JP2013523271A JP2013532729A5 JP 2013532729 A5 JP2013532729 A5 JP 2013532729A5 JP 2013523271 A JP2013523271 A JP 2013523271A JP 2013523271 A JP2013523271 A JP 2013523271A JP 2013532729 A5 JP2013532729 A5 JP 2013532729A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- liquid
- pharmaceutically acceptable
- formulation according
- intravenous administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims description 9
- 239000012669 liquid formulation Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 229960001021 lactose monohydrate Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000004615 ingredient Substances 0.000 claims 3
- -1 isoindole-2 (1H) -yl Chemical group 0.000 claims 3
- 238000004090 dissolution Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010069586 Orthopox virus infection Diseases 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- LSFUGNKKPMBOMG-UHFFFAOYSA-N cycloprothrin Chemical compound ClC1(Cl)CC1(C=1C=CC=CC=1)C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 LSFUGNKKPMBOMG-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37097110P | 2010-08-05 | 2010-08-05 | |
| US61/370,971 | 2010-08-05 | ||
| US201161450359P | 2011-03-08 | 2011-03-08 | |
| US61/450,359 | 2011-03-08 | ||
| PCT/US2011/046260 WO2012018810A1 (en) | 2010-08-05 | 2011-08-02 | St-246 liquid formulations and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532729A JP2013532729A (ja) | 2013-08-19 |
| JP2013532729A5 true JP2013532729A5 (https=) | 2014-09-18 |
| JP5898196B2 JP5898196B2 (ja) | 2016-04-13 |
Family
ID=45559790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523271A Active JP5898196B2 (ja) | 2010-08-05 | 2011-08-02 | Ｓｔ−２４６液体製剤および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9233097B2 (https=) |
| EP (1) | EP2600715B1 (https=) |
| JP (1) | JP5898196B2 (https=) |
| KR (1) | KR101868117B1 (https=) |
| CN (2) | CN106074370A (https=) |
| AR (1) | AR082566A1 (https=) |
| AU (1) | AU2011285871B8 (https=) |
| BR (1) | BR112013002646B1 (https=) |
| CA (1) | CA2807528C (https=) |
| DK (1) | DK2600715T3 (https=) |
| IL (1) | IL224430B (https=) |
| MX (2) | MX347795B (https=) |
| SG (3) | SG10201506031UA (https=) |
| WO (1) | WO2012018810A1 (https=) |
| ZA (1) | ZA201300930B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8530509B2 (en) | 2003-06-20 | 2013-09-10 | Siga Technologies, Inc. | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| CN104414983B (zh) * | 2013-08-28 | 2018-09-04 | 山东新时代药业有限公司 | 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺 |
| WO2015077143A1 (en) | 2013-11-19 | 2015-05-28 | Siga Technologies, Inc. | Rehydration of micronized tecovirimat monohydrate |
| US10413517B2 (en) * | 2014-06-12 | 2019-09-17 | University Of Notre Dame Du Lac | Composition and method for the treatment of neurological diseases and cerebral injury |
| CN105816422B (zh) * | 2015-01-05 | 2020-08-14 | 天士力医药集团股份有限公司 | 一种水飞蓟宾注射剂及其制备方法 |
| US10488733B2 (en) | 2015-04-10 | 2019-11-26 | Bae Systems Plc | Long range electromagnetic radiation sensor having a control system to heat and/or ionize the air within three-dimensional portions of an atmospheric volume |
| CN107625967B (zh) * | 2016-07-15 | 2021-07-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种特考韦瑞注射用药物组合物及其制备方法 |
| CN107638571B (zh) * | 2016-07-15 | 2021-07-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种特考韦瑞口服药物组合物及其制备方法 |
| CN106407676A (zh) * | 2016-09-12 | 2017-02-15 | 广东省农业科学院动物科学研究所 | 一种基于蒙特卡罗模拟的抗菌药物药效计算方法 |
| US11413275B1 (en) | 2018-12-14 | 2022-08-16 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
| US10478422B1 (en) | 2018-12-14 | 2019-11-19 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
| US11446243B1 (en) * | 2019-08-05 | 2022-09-20 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
| US12226431B2 (en) * | 2021-09-11 | 2025-02-18 | Porosome Therapeutics, Inc. | Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses |
| CN116211821A (zh) * | 2023-02-06 | 2023-06-06 | 青岛增益安生物科技有限公司 | 一种特考韦瑞的药物混合方式 |
| US11903962B1 (en) | 2023-05-07 | 2024-02-20 | Michael Farber | Isoxazoline complexes and compositions thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003215027A1 (en) * | 2002-03-21 | 2003-10-08 | Regents Of The University Of Minnesota | Cyclodextrin compositions and methods of treating viral infections |
| EP1638938B1 (en) * | 2003-06-20 | 2017-04-12 | Siga Technologies Inc. | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| WO2006067584A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Limited | 8-aza-bicyclo (3.2.1) octane derivatives with an activity on chemokine ccr5 receptors |
| US8642577B2 (en) * | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| PT2583668E (pt) * | 2005-10-26 | 2015-01-05 | Cydex Pharmaceuticals Inc | Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação |
| PL2094308T3 (pl) * | 2006-11-21 | 2011-06-30 | Novartis Ag | Trwały preparat pozajelitowy zawierający inhibitor RSV o strukturze benzodiazepiny |
| CN104758281A (zh) * | 2007-04-23 | 2015-07-08 | 西佳技术公司 | 用于治疗和预防正痘病毒感染和相关疾病的化合物、组合物和方法 |
| WO2010014913A1 (en) * | 2008-08-01 | 2010-02-04 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
-
2011
- 2011-08-02 CA CA2807528A patent/CA2807528C/en active Active
- 2011-08-02 AU AU2011285871A patent/AU2011285871B8/en active Active
- 2011-08-02 CN CN201610599807.0A patent/CN106074370A/zh active Pending
- 2011-08-02 CN CN2011800480431A patent/CN103281898A/zh active Pending
- 2011-08-02 DK DK11815188.5T patent/DK2600715T3/da active
- 2011-08-02 SG SG10201506031UA patent/SG10201506031UA/en unknown
- 2011-08-02 SG SG10202105262QA patent/SG10202105262QA/en unknown
- 2011-08-02 MX MX2013001389A patent/MX347795B/es active IP Right Grant
- 2011-08-02 KR KR1020137005710A patent/KR101868117B1/ko active Active
- 2011-08-02 SG SG2013007000A patent/SG187243A1/en unknown
- 2011-08-02 JP JP2013523271A patent/JP5898196B2/ja active Active
- 2011-08-02 US US13/814,102 patent/US9233097B2/en active Active
- 2011-08-02 WO PCT/US2011/046260 patent/WO2012018810A1/en not_active Ceased
- 2011-08-02 EP EP11815188.5A patent/EP2600715B1/en active Active
- 2011-08-02 BR BR112013002646-4A patent/BR112013002646B1/pt active IP Right Grant
- 2011-08-02 MX MX2017006160A patent/MX368106B/es unknown
- 2011-08-04 AR ARP110102829A patent/AR082566A1/es not_active Application Discontinuation
-
2013
- 2013-01-27 IL IL224430A patent/IL224430B/en active IP Right Grant
- 2013-02-04 ZA ZA2013/00930A patent/ZA201300930B/en unknown
-
2015
- 2015-12-01 US US14/955,674 patent/US9907859B2/en active Active
-
2018
- 2018-01-16 US US15/872,505 patent/US10124071B2/en active Active
- 2018-10-11 US US16/157,343 patent/US10576165B2/en active Active
-
2020
- 2020-01-02 US US16/732,509 patent/US10864282B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532729A5 (https=) | ||
| JP2009102342A5 (https=) | ||
| JP2013542247A5 (https=) | ||
| WO2009033795A3 (en) | Use of a obestatin as a therapeutic agent | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| WO2009033683A3 (en) | Galanin message associated peptide alone or in combination with minigastrin as a therapeutic agent | |
| WO2010039762A3 (en) | Pharmaceutical compositions comprising boronic acid compounds | |
| WO2009033668A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009040068A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033762A3 (en) | Use of endothelin-3 as a therapeutic agent | |
| WO2009033768A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2013522229A5 (https=) | ||
| AU2009210655A1 (en) | Treatment of bladder diseases with a TLR7 activator | |
| WO2009033805A3 (en) | Use of somatostatin-14 as a therapeutic agent | |
| WO2009040029A3 (en) | Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis | |
| JP2013507415A5 (https=) | ||
| WO2009046867A3 (en) | Caerulein alone or in combination with acth (3-24 ) as therapeutic agent | |
| JP2013511557A5 (https=) | ||
| WO2009039988A3 (en) | Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection | |
| WO2009040028A3 (en) | Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis | |
| WO2009033712A3 (en) | Use of melanotan ii as a therapeutic agent | |
| WO2009033791A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009040005A9 (en) | Use of the peptide rfmwmr as a therapeutic agent | |
| WO2009033780A3 (en) | Use of growth hormone-releasing factor and/or k237 as a therapeutic agents | |
| WO2009040070A3 (en) | Use of helodermin as a therapeutic agent |